Predictors of early immunotherapy response in head and neck cancer: Per lesion analysis of a prospective randomized trial with nivolumab.
Yu Y, Chen L, Riaz N, Kang J, Tsai C, Sherman E, Lee N, McBride S. Predictors of early immunotherapy response in head and neck cancer: Per lesion analysis of a prospective randomized trial with nivolumab. Journal Of Clinical Oncology 2019, 37: 6041-6041. DOI: 10.1200/jco.2019.37.15_suppl.6041.Peer-Reviewed Original ResearchNon-irradiated lesionsOral cavity primariesRisk of progressionNeck cancerExact testLogistic regressionNeck primary sitePrimary tumor subsiteTrials of nivolumabPD-L1 statusLymph node metastasisMultivariate logistic regressionPredictors of responsePrimary tumor siteStereotactic body radiotherapyFisher's exact testElicit clinical responsesStable diseaseCheckpoint inhibitorsMetastatic headClinical responseFirst doseLiver metastasesMetastasis locationProgressive disease